Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada

Abstract

BackgroundCombination antiretroviral therapy (ART) has significantly increased survival among HIV-positive adults in the United States (U.S.) and Canada, but gains in life expectancy for this region have not been well characterized. We aim to estimate temporal changes in life expectancy among HIV-positive adults on ART from 2000–2007 in the U.S. and Canada.MethodsParticipants were from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), aged ≥20 years and on ART. Mortality rates were calculated using participants' person-time from January 1, 2000 or ART initiation until death, loss to follow-up, or administrative censoring December 31, 2007. Life expectancy at age 20, defined as the average number of additional years that a person of a specific age will live, provided the current age-specific mortality rates remain constant, was estimated using abridged life tables.ResultsThe crude mortality rate was 19.8/1,000 person-years, among 22,937 individuals contributing 82,022 person-years and 1,622 deaths. Life expectancy increased from 36.1 [standard error (SE) 0.5] to 51.4 [SE 0.5] years from 2000–2002 to 2006–2007. Men and women had comparable life expectancies in all periods except the last (2006–2007). Life expectancy was lower for individuals with a history of injection drug use, non-whites, and in patients with baseline CD4 counts <350 cells/mm3.ConclusionsA 20-year-old HIV-positive adult on ART in the U.S. or Canada is expected to live into their early 70 s, a life expectancy approaching that of the general population. Differences by sex, race, HIV transmission risk group, and CD4 count remain.

Sexual and reproductive health needs of HIV-positive people in Tehran, Iran: a mixed-method descriptive study

“…The significance of disease can be depicted by 35.3 million People Living with HIV (PLHIV) globally, 2.3 million new HIV-positive cases, and 1.6 million AIDS-related deaths in 2012 (2,3). Despite the considerable prevalence, incidence and mortality rate of HIV worldwide, it should be considered that recent curative methods such as combination Antiretroviral Therapies (ARTs) have changed HIV/AIDS to a manageable chronic disease and significantly increased the life expectancy among HIV-positive individuals under treatment (1,4). Evidence leaves no doubt that therapeutic interventions such as ARTs might influence the sexual activities of PLHIV.…”

HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy

“…Currently, HIV-infected patients who are treated with HAART have a near-normal life expectancy approaching that of the general population (2)(3)(4). HIV infection is the strongest risk factor for lymphoma with a 77-fold associated risk for non-Hodgkin lymphoma (NHL) and an 11-fold risk for Hodgkin lymphoma (5)(6)(7).…”

Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls

“…In spite of these challenges, combination antiretroviral therapy has transformed the prognosis for patients with HIV [35,36]. Opportunistic brain infections have vastly decreased, and this therapy has resulted in almost complete elimination of HIVassociated dementia.…”